Markery zapalenia, aktywacja płytek krwi i zaburzenia krzepnięcia w chorobach zapalnych jelit Markers of inflammation, activation of blood platelets and coagulation disorders in inflammatory bowel diseases

Inflammatory bowel disease (IBD) includes ulcerative colitis and Crohn’s disease. It is a group of chronic disorders characterized by inflammation of the gastrointestinal track with unknown etiology. Currently applied biomarkers include CRP, ESR, pANCA, ASCA, and fecal calprotectin. The etiopathogenesis of IBD is multifactorial. In patients with IBD in inflamed alimentary tract mucosa the number of recruited monocytes and activated macrophages which are source of cytokines. In IBD, the exacerbation is accompanied by thrombocytosis. Platelets play a crucial role in the hemostasis and inflammatory response. Selectins, which regulates the hemostasis and inflammatory response, stimulates the secretion of many inflammatory mediators such as β-thromboglobuline, CD40L, fibrinogen, IL-1β, platelet factor-4. In the course of IBD the following changes are observed: an increase in the number of platelets (reactive thrombocytosis), PDW and PCT, reduction in MPV, increased production and excretion of granular content products (P-selectin, GP53, β-TG, PF-4, vWF, fibrinolytic inhibitors). markers of inflammation • blood platelet • MPV • inflammatory bowel disease • IBD • activation Markery zapalenia, aktywacja płytek krwi i zaburzenia krzepnięcia w chorobach zapalnych jelit Markers of inflammation, activation of blood platelets and coagulation disorders in inflammatory bowel diseases Joanna Matowicka-Karna Department of Clinical Laboratory Diagnostics, Medical University of Bialystok J. Waszyngton’a 15A, 15-276 Bialystok, Poland